Skip to main content

Advertisement

Log in

Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy

Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy.

Methods

Retrospective analysis of a prospective database identified patients with MML who underwent liver resection from 1980 to 2008.

Results

A total of 539 patients had MML, and 39% (204 of 539) had tumor collected for TIL. A total of 17% (35 of 204) underwent liver resection for TIL. The 3-year overall survival was 53%. Lack of extrahepatic disease (P = .026), negative margin (P = .056), and single hepatic metastasis (P = .04) predicted survival after univariate analysis. Only lack of extrahepatic disease remained a significant predictor of survival after multivariate analysis (P = .043). A total of 31% (11 of 35) underwent complete resection without TIL, and 69% (24 of 35) underwent resection with synchronous intrahepatic and extrahepatic disease with intent to receive TIL. For 9 of 11 patients (2 of 11 excluded for gene therapy), 3-year survival was 80%. A total of 4 (44%) of 9 experienced recurrence, with a median disease-free survival of 1.2 years. For 24 patients (69%) with residual disease, 3-year survival was 51% (2 of 24 excluded for gene therapy). A total of 63% (15 of 24) received postoperative TIL (3-year survival 65%), and 29% (7 of 24) did not. A total of 40% (6 of 15) had disease that partially responded to TIL; the disease of 67% (4 of 6) had not progressed at median follow-up of 55 months (range, 42–197+ months). The seven patients who did not receive TIL had a median survival of 4.6 months.

Conclusions

Resection of MML with TIL should be considered because it can result in prolonged survival in a highly selected group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.

    CAS  PubMed  Google Scholar 

  3. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.

    CAS  PubMed  Google Scholar 

  4. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.

    CAS  PubMed  Google Scholar 

  5. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172–8.

    Article  PubMed  Google Scholar 

  6. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307–19.

    Article  CAS  PubMed  Google Scholar 

  7. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol. 2002;29:413–26.

    Article  CAS  PubMed  Google Scholar 

  8. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.

    CAS  PubMed  Google Scholar 

  9. Ahmann DL, Creagan ET, Hahn RG, et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989;63:224–7.

    Article  CAS  PubMed  Google Scholar 

  10. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950–5.

    Article  CAS  PubMed  Google Scholar 

  11. Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712–20.

    Article  PubMed  Google Scholar 

  12. Herman P, Machado MA, Montagnini AL, et al. Selected patients with metastatic melanoma may benefit from liver resection. World J Surg. 2007;31:171–4.

    Article  PubMed  Google Scholar 

  13. Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery. 1994;115:295–302.

    CAS  PubMed  Google Scholar 

  14. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol. 2004;16:155–60.

    Article  PubMed  Google Scholar 

  15. Reddy SK, Barbas AS, Marroquin CE, et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg. 2007;204:372–82.

    Article  PubMed  Google Scholar 

  16. Papachristou DN, Fortner JJ. Surgical treatment of metastatic melanoma confined to the liver. Int Surg. 1983;68:145–8.

    CAS  PubMed  Google Scholar 

  17. Ollila DW, Morton DL. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am. 1998;8:183–96.

    CAS  PubMed  Google Scholar 

  18. Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975–9;979–80.

    Google Scholar 

  19. Mondragon-Sanchez R, Barrera-Franco JL, Cordoba-Gutierrez H, Meneses-Garcia A. Repeat hepatic resection for recurrent metastatic melanoma. Hepatogastroenterology. 1999;46:459–61.

    CAS  PubMed  Google Scholar 

  20. Foster JH. Survival after liver resection for secondary tumors. Am J Surg. 1978;135:389–94.

    Article  CAS  PubMed  Google Scholar 

  21. Branum GD, Epstein RE, Leight GS, Seigler HF. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery. 1991;109:127–31.

    CAS  PubMed  Google Scholar 

  22. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524–35.

    Article  PubMed  Google Scholar 

  23. Rosenberg SA. The emergence of modern cancer immunotherapy. Ann Surg Oncol. 2005;12:344–6.

    Article  PubMed  Google Scholar 

  24. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.

    Article  CAS  PubMed  Google Scholar 

  25. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.

    Article  CAS  PubMed  Google Scholar 

  26. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.

    Article  CAS  PubMed  Google Scholar 

  27. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

National Institutes of Health National Cancer Institute, Intramural grant, provided support for the Surgery Branch, Immunotherapy Section.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Itzhak Avital MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ripley, R.T., Davis, J.L., Klapper, J.A. et al. Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy. Ann Surg Oncol 17, 163–170 (2010). https://doi.org/10.1245/s10434-009-0677-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0677-0

Keywords

Navigation